Latest news and press releases about Annovis Bio, Inc. (ANVS): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases.
Price
| Price | $1.04 |
| Market Cap | $44M |
| Exchange | NYSE |
| Country | US |
Valuation Ratios
| Price / Book | -7.41 |
| EV / EBITDA | -0.82 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -685.96% |
| Return on Invested Capital | -400.40% |
| Return on Assets | -224.73% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ATNM · BCAB · BTAI · CELU · ELUT · EVAX · MAIA
Explore sector: Healthcare · Biotechnology
More sections of ANVS: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks